Rhumbline Advisers X4 Pharmaceuticals, Inc Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Rhumbline Advisers holds 178,478 shares of XFOR stock, worth $108,871. This represents 0.0% of its overall portfolio holdings.
Number of Shares
178,478
Previous 187,246
4.68%
Holding current value
$108,871
Previous $108,000
10.19%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding XFOR
# of Institutions
103Shares Held
99.9MCall Options Held
213KPut Options Held
50.6K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$10.3 Million2.03% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$9.14 Million0.77% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$6.51 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.44MShares$5.15 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$4.35 Million0.11% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $41.9M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...